Latest news
Bottneuro Team
Dr Antonella Santuccione Chadha joins the Board of Directors at Bottneuro
It is an honor to welcome Dr. Antonella Santuccione Chadha to the Board of Directors at Bottneuro AG - bringing her extensive expertise to build our clinical strategy, supporting the company’s mission to bring precision neuromodulation solutions to Alzheimer’s disease and beyond.
02 June, 2025
Read more
Bottneuro Team | Mon 06, 2025
Dr Antonella Santuccione Chadha joins the Board of Directors at Bottneuro
It is an honor to welcome Dr. Antonella Santuccione Chadha to the Board of Directors at Bottneuro AG - bringing her extensive expertise to build our c...
Bottneuro Team | Wed 05, 2025
Bottneuro Announces Leadership Changes
Dr Thomas Hefti is joining as Chief Executive Officer of Bottneuro AG, Switzerland as of June 1. Dr Bekim Osmani, co-founder and current CEO, will ass...
Business Update | Fri 05, 2025
Bottneuro Launches Miamind.ch
Bottneuro AG announces the launch of miamind.ch, the official online platform for the Miamind® Neurostimulator.
Publication | Thu 05, 2025
Bottneuro publishes it's first publication in NeuroImage
Our team’s first publication in NeuroImage presents a novel approach to personalized brain stimulation using 3D-printed caps with flexible electrode p...
Business Update | Wed 12, 2024
Kopfwehzentrum Hirslanden joins Priority Access Program
We are happy to welcome the Kopfwehzentrum Hirslanden as an early adopter of our Priority Access Program for migraine patients!
Business Update | Wed 11, 2024
Dr. Filip Barinka joins Priority Access Program
We are thrilled to announce that Dr. Filip Barinka at the Altersneurologie Gedächtnis-Sprechstunde, in collaboration with the Swiss Neuro Radiology In...
Business Update | Wed 11, 2024
Bellevue Medical Group joins Priority Access Program
We are excited to introduce the Bellevue Medical Group (BMG) as an early adopter of our Priority Access Program for Alzheimer’s patients!
Featured | Tue 11, 2024
Tagesanzeiger Article
We’re proud to announce that our article has been featured in the latest edition of Tages-Anzeiger.
Business Update | Thu 10, 2024
TOP Swiss Medtech Startups 2024
Proud to announce that Bottneuro was selected as one of 15 of the most promising Swiss MedTech Startups and Scale-Ups of 2024.
Featured | Mon 08, 2024
Featured Article about the Priority Access Program on Startupticker
A new article about Bottneuro's Priority Access Program has just been published on Startupticker, Switzerland's leading platform for startup news and...
Bottneuro Team | Mon 06, 2024
Dr. Antonella Santuccione Chadha joined as an Advisor
Dr Antonella Santuccione Chadha is joining Bottneuro as an advisor!
Business Update | Wed 05, 2024
Priority Access Program
As part of our Priority Access Program, we are offering neurology clinics in Switzerland up to 25 Miamind® devices for young people with mild and mode...
Business Update | Mon 04, 2024
Advancing Neurological Care Across the EU with Bottneuro GmbH
Join Us in Advancing Neurological Care Across the EU with Bottneuro GmbH
Events & Conferences | Mon 04, 2024
Bottneuro at the Mental & Brain Tech Tour 2024
Bottneuro has been chosen as one of the top 32 companies to present at the Mental & Brain Tech Tour 2024!
Events & Conferences | Wed 04, 2024
Bottneuro at the BOOM Summit 2024
Bottneuro is excited for two healthtech-filled days at BOOM Summit 2024 in Basel, Switzerland.
Business Update | Wed 04, 2024
European patent granted
Bottneuro AG has been granted an important patent!
Featured | Tue 04, 2024
Bottneuro's Miamind Neurostimulator Spotlighted in Uni Basel Article
Bottneuro's Miamind® Neurostimulator has been featured in an article published by the University of Basel.
Events & Conferences | Mon 03, 2024
Bottneuro at the LSIUSA24
Alois Hopf, CSO of Bottneuro, is representing Bottneuro AG at the LSIUSA24 in Dana Point, California.
Business Update | Fri 03, 2024
MINDSTIM study has successfully concluded
Our first clinical trial, MINDSTIM has successfully concluded!
Business Update | Mon 03, 2024
Start of the intervention phase of the MINDSTIM study
Our very first devices are now complete and ready for the intervention phase of the MINDSTIM clinical trial with our personalized neurostimulator at t...
Publication | Tue 01, 2024
Bottneuro publishes Whitepaper
Read more about the technology, our customized Miamind® Neurostimulator and the opportunity the recent registration at Swissmedic and MHRA offers in o...
Business Update | Thu 01, 2024
The MINDSTIM clinical trial officially started!
A new year, another Milestone in Bottneuro’s journey to develop a non-invasive Alzheimer’s Disease therapy. The MINDSTIM clinical trial officially sta...
Business Update | Fri 11, 2023
Miamind® Neurostimulator officially registered with Swissmedic and MHRA
Excellent news for patients. After three years of development, Miamind®, the patient-specific neurostimulator for non-invasive brain stimulation, can...
Events & Conferences | Mon 11, 2023
Bottneuro at MEDICA 2023
Bottneuro is attending the this years MEDICA conference in Düsseldorf, Germany, one of the largest medical B2B trade fairs globally!
Events & Conferences | Mon 10, 2023
Bottneuro at the Biosensors for Medical Wearables Conference
The Biosensors for Medical Wearables Conference is back in Boston!
Events & Conferences | Mon 10, 2023
Bottneuro at the UK Medtech Mission for Swiss Start-ups
The UK Medtech Mission for Swiss Start-ups is set to kick off, and Bottneuro is thrilled to have been selected to be a part of this exciting week!
Events & Conferences | Tue 09, 2023
Bottneuro at the Swiss Medtech Expo Symposium
At the Swiss Medtech Expo symposium on Wednesday, September 13, 2023, everything will revolve around application examples from manufacturing.
Business Update | Fri 09, 2023
Miamind® Neurostimulator Achieves Official Certification from DEKRA
Bottneuro has received official confirmation from DEKRA that the Miamind® Neurostimulator has successfully passed all relevant external device tests.
Bottneuro Team | Sat 07, 2023
Prof. Christoph Michel joined as an Advisor
As EEG measurements play a crucial role for diagnosis and monitoring of #Alzheimer's Disease, we are delighted to welcome Prof. Christoph Michel as ou...
Bottneuro Team | Mon 05, 2023
Prof. Dr. Emiliano Santarnecchi joined as an Advisor
We are thrilled to announce that Prof. Dr. Emiliano Santarnecchi has joined Bottneuro as our new scientific advisor
Business Update | Mon 03, 2023
Followup to Bottneuro's collaboration with Samsung!
Today Bottneuro was featured in Samsung Global Newsroom, Samsung Mobile and several newspapers in South Korea.
Business Update | Wed 02, 2023
Partnership Samsung & Bottneuro
Bottneuro has entered into a technology partnership with Samsung to support its innovative approach to treating Alzheimer's disease.
Events & Conferences | Wed 02, 2023
Supporter of the Dementia Conference in Bern 2023
Bottneuro is supporter of the Demencia Conference in Bern 2023.
Business Update | Wed 06, 2022
Latest headset design
Happy to show the latest design of our 3D-printed, personalized headset for neuromodulation therapies.
Events & Conferences | Tue 03, 2022
Supporter at the Dementia Conference in Bern 2022
We are happy to announce that Bottneuro will participate as supporter at the Dementia Conference in Bern on April 28th, where diagnostics and early de...
Business Update | Thu 03, 2022
Bottneuro moves to a new location
This February we were already able to move into our new office. it is still located on the Novartis Campus, but in a different building on the 12th fl...
Business Update | Fri 12, 2021
Bottneuro wins CHF 150,000 to advance diagnosis and digital therapies for Alzheimer’s disease
Business Update | Mon 11, 2021
Switzerland advances personalized Alzheimer’s therapy
Tokyo (SCCIJ) – The two Swiss-based companies Positrigo and Bottneuro have joined forces to foster the early diagnosis and personalized treatment of A...
Business Update | Thu 11, 2021
BottNeuro advancing personalized alzheimer’s therapy
Bottneuro is working on the development of personalized therapies to treat Alzheimer’s disease in which certain areas of a patient’s brain are stimula...
Business Update | Thu 07, 2021
Bottneuro passes 2nd stage of Venture Kick: CHF 40'000.-
Bottneuro was selected by the Venture Kick's jury of experts as one of the winners of the second stage of financial and entrepreneurial support.
Business Update | Tue 03, 2021
BottNeuro passes 1st stage of Venture Kick: CHF 10'000.-
Bottneuro, together with Aegis Rider, Arkaïya, Celerato, and voltWALL win Venture Kick's first stage of financial and entrepreneurial support. Their p...
Business Update | Wed 02, 2021
Spin-Offs to Watch 2021: BottNeuro on Forbes DACH
Spin-Offs To Watch 2021": Bottneuro AG selected as one of the 30 most promising spin-offs in the DACH region! Bottneuro entwickelt ultradünne Implant...
Business Update | Thu 02, 2021
BottNeuro advancing personalized Alzheimer’s therapy
Basel-based startup Bottneuro is working on the development of personalized therapies to treat Alzheimer’s disease in which certain areas of a patient...
Business Update | Thu 08, 2019
Gebert Rüf supports NENI project with CHF 300'000.-
NENI – Nano Engineered Neural Interfaces